The utility of inhibitory quotients in determining the relative potency of protease inhibitors

被引：13

作者：

Piliero, PJ ^{[1
]}

机构：

[1] Albany Med Coll, Div Clin Pharmacol, Albany, NY 12208 USA

来源：

AIDS | 2002年 / 16卷 / 05期

关键词：

D O I：

10.1097/00002030-200203290-00020

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：799 / 800

页数：2

共 5 条

[1] Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors [J].

Acosta, EP ;

Kakuda, TN ;

Brundage, RC ;

Anderson, PL ;

Fletcher, CV .

CLINICAL INFECTIOUS DISEASES, 2000, 30 :S151-S159

[2] Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy [J].

Condra, JH ;

Petropoulos, CJ ;

Ziermann, R ;

Schleif, WA ;

Shivaprakash, M ;

Emini, EA .

JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (03) :758-765

[3] Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study [J].

Durant, J ;

Clevenbergh, P ;

Garraffo, R ;

Halfon, P ;

Icard, S ;

Del Giudice, P ;

Montagne, N ;

Schapiro, JM ;

Dellamonica, P .

AIDS, 2000, 14 (10) :1333-1339

[4] In vitro effect of alpha(1)-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: A comparative study with other relevant HIV protease inhibitors [J].

Lazdins, JK ;

Mestan, J ;

Goutte, G ;

Walker, MR ;

Bold, G ;

Capraro, HG ;

Klimkait, T .

JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (05) :1063-1070

[5]

PISCITELLI S, 2001, IS IOPINAVIR RITONAV

← 1 →